A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults | MicrobiomeTrials
A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2022-08-05Est. Completion: 2024-09-09
Enrollment target: 68 participants
Locations
CIC Cochin, Paris, Paris Cedex 14, France
Hôpital Henri Mondor, Créteil, Paris, France
CHUV, Lausanne, Canton of Vaud, Switzerland
Chelsea and Westminster Hospital, London, United Kingdom
Other microbiome trials you might be interested in